STE
STERIS plc
NYSE · Healthcare · Medical - Devices · IE
$225.05
−0.78%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.0B | 5.9B | 5.5B | 5.1B | 4.5B |
| Cost of Revenue | 3.4B | 3.3B | 3.1B | 2.9B | 2.6B |
| Gross Profit | 2.7B | 2.6B | 2.4B | 2.2B | 2.0B |
| Operating Expenses | |||||
| R&D Expense | 115.1M | 112.9M | 107.6M | 103.7M | 98.5M |
| SG&A Expense | 1.1B | 1.4B | 1.3B | 1.3B | 1.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 372.4M | 4.1M | 94.2M | 26.0M | 485.0K |
| Total Operating Expenses | 1.5B | 1.5B | 1.5B | 1.4B | 1.2B |
| Cost and Expenses | 4.9B | 4.8B | 4.6B | 4.3B | 3.7B |
| Operating Income (EBIT) | 1.1B | 1.1B | 866.6M | 836.1M | 791.1M |
| Non-Operating | |||||
| Interest Income | 4.2M | 9.8M | 8.4M | 11.0M | — |
| Interest Expense | 60.6M | 60.7M | 86.3M | 144.4M | 110.8M |
| Net Interest Income | (56.4M) | (50.9M) | (77.9M) | (133.3M) | (110.8M) |
| Other Non-Op Income/Expense | (52.7M) | (54.5M) | (70.4M) | (133.3M) | (110.8M) |
| Non-Operating Income (excl Interest) | 3.4M | (6.2M) | (15.8M) | (11.0M) | (20.9M) |
| EBT (Pre-Tax Income) | 1.1B | 1.0B | 796.2M | 702.8M | 680.3M |
| Income Tax Expense | 280.8M | 262.2M | 184.7M | 149.5M | 124.1M |
| Bottom Line | |||||
| Net Income | 805.1M | 785.1M | 614.6M | 378.2M | 107.0M |
| Earnings from Cont. Ops | 808.1M | 785.1M | 611.6M | 553.3M | 556.2M |
| Earnings from Discont. Ops | — | — | 4.5M | (173.2M) | (450.4M) |
| Bottom Line Net Income | 805.1M | 785.1M | 614.6M | 378.2M | 107.0M |
| Per Share | |||||
| Basic EPS | $8.20 | $7.93 | $6.24 | $3.83 | $1.07 |
| Diluted EPS | $8.18 | $7.93 | $6.20 | $3.81 | $1.07 |
| Revenue Per Share | $61.86 | $60.45 | $55.38 | $52.02 | $45.50 |
| Shares | |||||
| Basic Shares Outstanding | 97.6M | 98.2M | 98.6M | 98.8M | 99.7M |
| Diluted Shares Outstanding | 97.9M | 98.7M | 99.1M | 99.4M | 100.2M |
| Profitability Metrics | |||||
| EBITDA | 1.8B | 1.6B | 1.4B | 1.4B | 1.2B |
| D&A | 671.3M | 486.5M | 476.2M | 565.2M | 422.5M |
| EBIT | 1.1B | 1.1B | 882.5M | 847.2M | 812.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026